RANDOMIZED CONTROLLED MULTICENTER STUDY OF THE PREVENTION OF COMPLICATIONS BY OCTREOTIDE IN PATIENTS UNDERGOING SURGERY FOR CHRONIC-PANCREATITIS

A randomized double-blind placebo-controlled multicentre trial was car ried out in 247 patients undergoing major elective surgery for chronic pancreatitis to clarify whether the perioperative application of octr eotide prevents significant)). postoperative complications. Eleven com plications were defined, including death, anastomotic leakage, pancrea tic fistula, abscess, fluid collection, shock, sepsis, bleeding, pulmo nary insufficiency, renal insufficiency and postoperative pancreatitis . A total of 124 patients underwent pancreatic head resection, 55 left resection, 61 pancreaticojejunostomy and seven had other procedures. The overall mortality rate was 1.2 per cent (octreotide group 0.8 per cent, placebo group 0.4 per cent (P not The postoperative complication rate in the octreotide group was 16.4 per cent (20 of 122 patients) a nd in the placebo group 29.6 per cent (37 of 125) (P<0.007). The perio perative application of octreotide substantially reduces the risk of p ostoperative complications in patients undergoing major pancreatic sur gery for chronic pancreatitis.